185 related articles for article (PubMed ID: 21814800)
1. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
Yamagishi Y; Terada M; Ohki E; Miura Y; Umemura T; Mikamo H
J Infect Chemother; 2012 Feb; 18(1):127-9. PubMed ID: 21814800
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
3. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
Sugimoto N; Yamagishi Y; Mikamo H
J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
[TBL] [Abstract][Full Text] [Related]
4. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
[TBL] [Abstract][Full Text] [Related]
5. Superior effect of tazobactam/piperacillin compared to piperacillin on beta-lactamase-producing Pseudomonas aeruginosa.
Nishida K; Higashitani F; Hyodo A
Chemotherapy; 1997; 43(3):171-8. PubMed ID: 9142457
[TBL] [Abstract][Full Text] [Related]
6. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
Gentry CA; Williams RJ
Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
[TBL] [Abstract][Full Text] [Related]
7. [In vitro synergistic effects of tazobactam/piperacillin with various antibiotics].
Nishida K; Niidome K; Hashimoto M; Otsuki M; Nishino T
Jpn J Antibiot; 1994 Oct; 47(10):1348-62. PubMed ID: 7807695
[TBL] [Abstract][Full Text] [Related]
8. [Laboratory and clinical studies on tazobactam/piperacillin in the field of pediatrics].
Kuno K; Ogawa A; Hayakawa F; Miyajima Y; Takahashi H; Okumura A; Kato T; Itomi K
Jpn J Antibiot; 1998 Jun; 51(6):395-406. PubMed ID: 9755829
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
10. [In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Feb; 55(1):61-6. PubMed ID: 11977921
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetic and clinical evaluation of tazobactam/piperacillin in the pediatric field].
Toyonaga Y; Ishihara T; Tezuka T; Nakamura H
Jpn J Antibiot; 1998 May; 51(5):325-45. PubMed ID: 9693966
[TBL] [Abstract][Full Text] [Related]
12. [A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia].
Oizumi K; Ohno T; Kawahara M; Kawaguchi S; Saisho M; Mitutake Y; Saito A; Tomizawa M; Koike T; Takebe K
Jpn J Antibiot; 1995 Apr; 48(4):449-81. PubMed ID: 7783313
[TBL] [Abstract][Full Text] [Related]
13. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
Tamma PD; Turnbull AE; Milstone AM; Hsu AJ; Carroll KC; Cosgrove SE
Clin Infect Dis; 2012 Sep; 55(6):799-806. PubMed ID: 22696019
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
[TBL] [Abstract][Full Text] [Related]
15. [Clinical studies of tazobactam/piperacillin (TAZ/PIPC) in pediatric patients].
Waga S; Yokoyama M; Tsushima T; Chiba C; Saito T; Okamoto T; Asuka T; Kitazawa J; Tateyama N; Sato Y; Takahashi Y
Jpn J Antibiot; 1998 May; 51(5):305-18. PubMed ID: 9693964
[TBL] [Abstract][Full Text] [Related]
16. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective Analysis of Factors Decreasing the Efficacy of Tazobactam/Piperacillin for Pneumonia in Elderly Patients].
So M; Oda K; Ota K; Sakamoto N; Suzuki T
Yakugaku Zasshi; 2018; 138(4):581-588. PubMed ID: 29608008
[TBL] [Abstract][Full Text] [Related]
18. [Comprehensive evaluation of pharmacokinetic and clinical studies on tazobactam/piperacillin in pediatric field].
Fujii R; Okuno A; Fujita K; Yoshikawa M; Inyaku F; Takimoto M; Saijo M; Wagatsuma S; Fukushima N; Ishikawa A
Jpn J Antibiot; 1995 Mar; 48(3):311-45. PubMed ID: 7752448
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
Yamamoto Y; Izumikawa K; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Tsukamoto M; Kakeya H; Yanagihara K; Yasuoka A; Kohno S
J Infect Chemother; 2013 Apr; 19(2):291-8. PubMed ID: 23345050
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
